Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Department of Clinical Pharmacology, School of Pharmacy, Nanjing University, Nanjing, China.
J Mater Sci Mater Med. 2022 May 10;33(5):42. doi: 10.1007/s10856-022-06663-6.
This study aims to evaluate the feasibility and cardio-protective effects of biocompatible silicon-built restraint device (ASD) in the rat's heart failure (HF) model. The performance and compliance characteristics of the ASD device were assessed in vitro by adopting a pneumatic drive and ball burst test. Sprague-Dawley (SD) rats were divided into four groups (n = 6); control, HF, HF + CSD, and HF + ASD groups, respectively. Heart failure was developed by left anterior descending (LAD) coronary artery ligation in all groups except the control group. The ASD and CSD devices were implanted in the heart of HF + ASD and HF + CSD groups, respectively. The ASD's functional and expansion ability was found to be safe and suitable for attenuating ventricular remodeling. ASD-treated rats showed normal heart rhythm, demonstrated by smooth -ST and asymmetrical T-wave. At the same time, hemodynamic parameters of the HF + ASD group improved systolic and diastolic functions, reducing ventricular wall stress, which indicated reverse remodeling. The BNP values were reduced in the HF + ASD group, which confirmed ASD feasibility and reversed remodeling at a molecular level. Furthermore, the HF + ASD group with no fibrosis suggests that ASD has significant curative effects on the heart muscles. In conclusion, ASD was found to be a promising restraint therapy than the previously standard restraint therapies. Stepwise ASD fabrication process (a) 3D computer model of ASD was generated by using Rhinoceros 5.0 software (b) 3D blue wax model of ASD (c) Silicon was prepared by mixing the solutions (as per manufacturer instruction) (d) Blue wax model of ASD was immersed into liquid Silicon (e) ASD model was put into the oven for 3 hours at 50 °C. (f) Blue wax started melting from the ASD model (g) ASD model was built from pure silicon (h) Two access lines were linked to the ASD device, which was connected with an implantable catheter (Port-a-cath), scale bar 100 µm. (Nikon Ldx 2.0).
本研究旨在评估生物相容性硅制约束装置(ASD)在大鼠心力衰竭(HF)模型中的可行性和心脏保护作用。采用气动驱动和球爆裂试验对 ASD 装置的性能和顺应性特征进行了体外评估。Sprague-Dawley(SD)大鼠分为四组(n=6);对照组、HF 组、HF+CSD 组和 HF+ASD 组。除对照组外,所有组均通过左前降支(LAD)冠状动脉结扎建立心力衰竭。ASD 和 CSD 装置分别植入 HF+ASD 和 HF+CSD 组的心脏中。ASD 的功能和扩张能力被发现是安全的,适合减轻心室重构。ASD 治疗的大鼠表现出正常的心律,由平滑的 ST 和不对称的 T 波证实。同时,HF+ASD 组的血液动力学参数改善了收缩和舒张功能,降低了心室壁应力,表明心室重构逆转。HF+ASD 组的 BNP 值降低,这证实了 ASD 在分子水平上的可行性和心室重构逆转。此外,HF+ASD 组无纤维化表明 ASD 对心肌有显著的治疗效果。总之,ASD 被发现是一种有前途的约束治疗方法,优于以前的标准约束治疗方法。ASD 逐步制造工艺(a)使用 Rhinoceros 5.0 软件生成 ASD 的 3D 计算机模型(b)ASD 的 3D 蓝色蜡模(c)按制造商说明混合溶液制备硅(d)将蓝色蜡模浸入液态硅中(e)将 ASD 模型放入烤箱中在 50°C 下放置 3 小时(f)蓝色蜡开始从 ASD 模型中融化(g)从纯硅中构建 ASD 模型(h)将两条接入线连接到 ASD 装置上,该装置与可植入导管(Port-a-cath)相连,标尺 100µm。(Nikon Ldx 2.0)。